Five Prime, Inhibrx deal has first 'breakthrough' milestones
This article was originally published in Scrip
Executive Summary
A collaboration and license agreement between Five Prime Therapeutics and Inhibrx appears to be the first-ever drug development deal that offers extra milestone fees for product candidates that are able to win a coveted breakthrough therapy designation from the US FDA.